Juan José Infante

Bionaturis Group shows its premium solutions for human and animal health to the Bio International Convention 2016

The Bio International Convention 2016 once again will be an essential meeting point in the Bionaturis Group schedule. This event, considered the most important in the biotech sector worldwide, will be held on 6-9th of June in San Francisco (California).

Bionaturis Group is present at the Bio Convention 2016 after a year in which it has strengthened its positioning in the US market after the signing of a contract between Biobide and the US National Institute of Environmental Health (NIEHS), one of the most prestigious and demanding health institutions in the world. Biobide, the Bionaturis Group company that are experts in the use of the zebrafish model, also founded a subsidiary in Maryland in the same year.

In addition, Bionaturis will also highlight at the Bio Convention 2016 the new premium solutions in its portfolio which includes six new developments, five of which are for animal health.  These new developments point to several high-relevance diseases in livestock and pets, such as atopic dermatitis, osteoarthritis (or arthrosis) and different types of cancer. The global Animal Health sector represented an annual figure of $100 billion in 2014. In this area, drugs and vaccines reach until $23 billion (USD) with a CAGR of 6% for 2013-2017.

Bionaturis Group delegates in this edition are the chief scientific officer in Bionaturis, Juan J. Infante, the general Manager of Biobide, Andoni Cruz, and the Global Sales Manager in Bionaturis Group, Eli Kehrli. Biobide’s booth is in the Biobosque Region, inside the Spanish Pavillion (Booth 605). The applications of one-to-one meetings with Bionaturis Group delegates can be arranged emailing to eli.kehrli@bionaturis.com.

Consolidation and new contacts

The main goals of Bionaturis Group in this worldwide event are focused on the consolidation and monitoring of current customers and […]

June 6th, 2016|Blog english, congress|Comments Off|

Bionaturis takes part in the Innovation Forum of La Rioja

Bionaturis chief scientific officer, Dr. Juan Jose Infante, will participate as one of the lecturers in La Rioja’s Innovation Forum. The meeting will be celebrated in the Exhibition and Conference Center of La Rioja the next May 17-18th. Dr. Infante will be lecturing in the ‘Talk Show’ entitled “Bioeconomy and Agro-Food Sector” along with other three experts in this area.

Juan Jose Infante is Phd at Sciences and combines his work leading the development of biological products in Bionaturis with teaching Biotechnology in the Pablo de Olavide University of Seville. He joined Bionaturis in 2007, after a period as senior scientist in the University of Washington in Seattle, USA. In Bionaturis, Dr. Infante has been the principal investigator in the laboratory that developed Bionaturis’ proprietary FLYLIFE platform for manufacturing of biological medicines.

In the previous nine editions, this event has gathered 300 lecturers and more than 7,500 attendants. In this year’s edition, it will address key topics such as alliances of strategic sectors of the Bioeconomy like Food and Agriculture, the reduction of the environmental impact of companies, and potentiation of food control and safety procedures.

Dr. Infante will represent Bionaturis Group, including the matrix company Bionaturis and Biobide and ZIP Solutions. As a general topic, Dr. Infante will address the contribution of the biotech companies in the consolidation of Bioeconomy as a key sector of development. Regarding the Agro-Food, he will review the experience of Bionaturis in developing bio-based innovative solutions for increasing livestock productivity by using preventive measures and immunomodulators, which will lead to a decrease in the use of antibiotics in this sector. Antibiotic resistance has become a serious global health problem. According to the World Health Organization, this situation causes 300,000 deaths every […]

May 12th, 2016|Blog english, congress|Comments Off|

Bionaturis Group takes part in the development of a vaccine against cervical cancer

The Centre for the Development of Industrial Technology (CDTI, in Spanish) has granted an incentive of 184.847,40 Euros to the company from the European Programme Eurostars
The project is led by the German company BioEnergy GmbH & Consultant with participation from the German Cancer Research Center

Jerez de la Frontera, January 12nd 2016. Bionaturis Group will take part in the development of a cost-effective and possibly oral vaccine against cervical cancer. The initiative, led by the German company BioEnergy GmbH & Consultant with the participation of the German Cancer Research Center, receives funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.

According to the World Health Organization (WHO), developing countries suffer the highest impact from cervical cancer, which is caused by the Human Papillomavirus (HPV). Currently available vaccines are at a price point that makes them unaffordable for most people in developing countries. In addition to the loss of human lives, this circumstance leaves a large gap in the global coverage against the disease. With this project, Bionaturis Group is taking part in an alternative strategy to produce a cost-effective vaccine that will be affordable for the most highly impacted regions, following its vision of ‘A Global Access To Health’.

“This project is a real and relevant challenge for Bionaturis because, with it, we are expanding our horizons. Our acquired technological expertise in both vaccine development and cost effective manufacturing platforms lets us face this initiative with the realistic goal of providing to the population at risk a first-in-class drug that will be affordable given the social and economic conditions of their countries”, Bionaturis CSO, Juan Jose Infante, has stated.

The WHO highlights that cervical cancer caused […]

January 12th, 2016|Blog english, Press Releases|Comments Off|

Bionaturis Group consolidates its international scope in 2015 Bio Convention

Bionaturis and BBD BioPhenix – the two companies that comprise the Bionaturis Group -  have solidified their international scope in the latest edition of the Bio Convention, held this year in Philadelphia and considered an annual landmark in the worldwide biotech sector. During the event, our delegates engaged in significant one-on-one meetings with current and future customers demonstrating the increasing interest in the Group.

Bionaturis Development Area Manager, Dr. Juan Jose Infante; BBD BioPhenix General Manager, Mr. Andoni Cruz; and the Global Sales Manager, Mr. Eli Kehrli, were the Group’s delegates at the most important global biotech event of the year which brings together more than 15,000 biotech companies from 65 different countries.

The main goals of Bionaturis were focused on the consolidation and monitoring of current customers and in establishing new contacts with future customers and partners. In human health, Bionaturis progressed in its collaboration with BMI, a strategic partner in the US, for the joint development and manufacture of a recently validated antiviral vaccine technology on the Groups expression platform, Flylife. In animal health, Bionaturis’ delegates, Dr. Infante and Mr. Kehrli, held bilateral meetings with the business development managers of the largest multinational vet companies that represented both current customers as well as potential future collaborators. During these meetings, they dealt with key issues for the licensing of products currently in Bionaturis’ portfolio.

According to Dr. Infante, “with a more and more complete portfolio, our potential partners can find in Bionaturis Group a wide variety of possibilities that positions Bionaturis Group as the perfect partner in the development of biological medicines for both human and animal health. Being conscious of the changing requirements of the market, our business model adapts perfectly to the needs of […]

June 29th, 2015|Blog english, congress|Comments Off|

Bionaturis attends CPhI in Paris

Bionaturis’ CSO, Juan Jose Infante, will attend this week the international pharmaceutical meeting CPhI, to be held in Paris. This event gathers in each edition more than 2,000 exhibitors and 34,000 attendees from more than 140 countries all over the world, thus it is considered a must-have in your calendar of  human and animal health events.

The forum (October 7-9) is also celebrating its 25 anniversary.

If you want to know more about this event, please click here

October 9th, 2014|Blog english, congress|Comments Off|

Bionaturis Group, at BioSpain 2014

Bionaturis Group is taking part this week in BioSpain 2014, the most important forum of this sector in Spain, that is being held in Santiago de Compostela. Bionaturis’ CSO, Juan Jose Infante, and BBD BioPhenix’s R&D Manager, Arantza Muriana, are the delegates of the companies in our stand (B9).

During these three days Bionaturis Group is meeting many high-level professionals. More and more institutions are relying on FLYLIFE special features and the versatility of the zebrafish, and so the activity of the delegates is intensive.

If you want to know more about BioSpain 2014, please click here
Follow the event in Twitter at #BioSpain2014

September 26th, 2014|Blog english, congress|Comments Off|

By FLYLIFE vaccines against diseases as Ebola could be manufactured

Bionaturis (ticker BNT) scientists have analyzed the situation on protection against this disease which, unfortunately, is on the news in recent weeks. Based on the antigenic capacity in murine models of the glycoprotein of the Ebola virus capside (S1090, Journal of Infection Diseases, 2011:204 – Suppl. 3-, Tsuda et to the), Bionaturis team could develop a recombinant vaccine in its FLYLIFE system. Bionaturis would follow similar strategies already successfully used for other vaccine developments based on this type of protein within the company.

According to Dr Juan Jose Infante, CSO of the company, “there are data showing that, properly presented, this antigen may confer protection against the Ebola virus in healthy patients. Bionaturis has the track record and necessary knowledge in recombinant antigen presentation to pursue a high rate of success. On the other hand, unlike other options being considered, such as the use of an attenuated virus to carry this protein, a recombinant vaccine strategy would be much more safer during the production and handeling and would have less uncertainty regarding safety in healthy vaccinated humans. In the event of a successful development using FLYLIFE, thanks to its features, Bionaturis could release batches of million doses within four weeks upon order receipt. Dealing with any emergency the population at risk would be protected, guaranteeing total safety for the rest”.

Bionaturis scientists estimate that within a maximum of 24 months it would be viable to deliver experimental doses of a hipothetical  new vaccine, with proven safety and efficacy tested in animal models and ready to be tested in primates and humans, or to be used in cases of emergency as the occurred in the last month. Bionaturis´team is evaluating the possibilities of development of this vaccine along with its commercial and technological […]

August 19th, 2014|Blog english, Press english|Comments Off|

Bionaturis’ vaccine against Visceral Canine Leishmaniasis, preventive and therapeutic

Bionaturis continues the development of BNT005, a vaccine against Visceral Canine Leishmaniasis, a disease that affects dogs and is spread in Mediterranean countries as Spain, being registered an increasing rate of zoonosis (when an animal disease infects humans) lately. The visceral one is the most serious type of Leishmaniasis and it can be lethal if it is not treated well. It is caused by the parasites Leishmania and transmitted by the bite of the phlebotomine sandfly that acts as a vector.

Nowadays there is not any vaccine already in the market to prevent or treat humans against this disease, being its development a priority of the World Health Organization (WHO). The current treatment with antiparasitics has undesirable side effects and it causes the outbreak of resistance phenomena in the parasite. However, for dogs there are few options approved in Europe and LATAM, that claim themselves as prophylactic but not therapeutic.

Dogs among rabbits are the main reservoir of Leishmaniasis. Because of that, its control is essential to avoid the spread of this disease in humans (zoonosis). “A vaccine against canine Leishmaniasis has a double goal. Firstly, in the animals, which will be protected or can be treated against a disease that is fatal in a high percentage of cases. And, secondly, in humans, who will have less possibilities of suffering the disease if their pets do not have the parasite or they have them under control”, Bionaturis’ CSO, Juan Jose Infante, has stated.

Tests in rodents and Beagle dogs

Infante has also stood out that “the difference between BNT005 by Bionaturis and others vaccine attempts to fight this disease is that the preliminary results obtained and published in the last annual management report show that Bionaturis’ vaccine induces […]

August 12th, 2014|Blog english, Press english|Comments Off|

Bionaturis Group enhances its international alliances in San Diego (USA)

Bionaturis and BBD Biophenix have taken part in the latest edition of Bio International Convention 2014, in San Diego (June 2014), where the hard-working days have strengthened the international strategies and alliances of the group.

Along three days, the delegates moved to San Diego, Juan Jose Infante (Bionaturis) and Arantza Muriana (BBD Biophenix), has had up to 60 high-level ‘One to One’ meetings, mixing follow-up meetings with already pharmaceutical and veterinarian clients with the evaluation of development opportunities with new ones. The managers of both companies in the Convention have stated: “They have been more than fruitful meetings to consolidate our relationships with current and future partners and to confirm how our join innovative portfolio is at the forefront of the industry, so that we expect to sign new contracts shortly”.

In particular, Bionaturis´ attention has been focused on its portfolio of biological products and the unique features of its FLYLIFE platform as well, whereas BBD has validated the relevance of zebra fish as animal model for increasing the screening success rate not only for the pharmaceutical sector but also for petrochemical, agrochemical, nutraceutical and cosmetics ones.

The Convention in San Diego has also provided a great opportunity to go further within the global expansion plan, with M&As and international growth in Asia and LATAM as  cornerstones.

Expositor

This year Bionaturis Group has participated as exhibitor within the Spanish pavilion, having a booth sponsored by Biobasque. The dynamism shown in this Convention and the record number of partnering meetings is a prove of a wealthy sector with high potential growth. The event showcased the official presentation of Bionaturis Group, after the recent acquisition of BBD Biophenix.

July 4th, 2014|Blog english, Press english|Comments Off|

Juan Jose Infante: “With Bionaturis, personalized medicine is here”

The unique features of FLYLIFE lead to make personalized medicine a real option. Getting a specific drug to fight a specific disease affecting a region wherever in the world is possible thanks to Bionaturis’ innovative approach. “Pathogens are changing, are mutating, different serotypes of the same bacteria are appearing and because of that, despite having vaccines, people continue getting sick and there are serious health problems in animal farms”, “in the vaccine world in particular and the health sector as a whole the time for ‘One size fits all’ is over. A disease is always slightly different in every single living organism and even it depends on the moment that affects the same organism, so it has to be the solution. It´s not hard to see efficacy rates under 60% of universal solutions in a specific region. Science and innovation are progressing a lot in this sense and more efficacy solutions are in hand but something has to change to these advances getting the patients”  Bionaturis’ CSO, Juan Jose Infante, has said.

As he explains in the following video, Bionaturis’ production platform suits the technological requirements to make cost-efficient medicines for skinny niche populations. To make it a real option and save lives, other non-technological issues have to be addressed.

Here you are the video

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR